-
Miranda Lambert Leads North Texans with Seven Grammy Nominations for 2027
-
DiDi Advances Robotaxi Operations in China with New R2 Vehicle and Expanded Safety Infrastructure
-
Smart Car Seats Tested: Do Sensors and Apps Actually Improve Safety?
-
XPENG Launches Two New Models in UK; Pony.ai Robotaxi Enters Pilot
-
RuffleButts + RuggedButts Featured in Hasbro's 2026 Holiday Gift Guide
-
Dermata Highlights Additional Results and Photos from Cosmetic Study Evaluating Its Tome Foundational Treatment
-
NexCore and MetLife Investment Management Launch $1.3 Billion Senior Living Co-Investment Venture
-
Tectonic Metals Completes Record Drill Program at Flat, Advances Five Pillars of Growth Toward Major 2027 Milestones
-
Glidewell Opens Applications for 2027 Guiding Leaders Cohorts in California and North Carolina
-
International Business Times UK Increases Programmatic Revenue by 30% with Opti Digital
-
Valion Bio Reports Completion of 200-Liter Entolimod Production Run; Material Supplying Ongoing AFRRI Study
-
Miami Allstars FC have Applied to Compete in the Women's Premier Soccer League, with the Club Targeting a 2027 or 2028 Debut in North Miami, Florida
-
Klique Joins Lenovo AI Innovators, Bringing Its Enterprise AI Control Plane to Lenovo Hybrid AI Factory
-
Waste Energy to Host Shareholder Update Today at 4:30 PM EST; Management to Discuss WE #1 Commissioning, Revenue Opportunities and Growth Strategy
-
FaZe Esports, a GameSquare Company, Wins Rainbow Six Championship at Osaka Major
-
Pinnacle Food Group Limited Achieves Laboratory-Scale Astaxanthin Extraction in Haematococcus pluvialis Program
-
BioLargo Reports Third Quarter 2026 Results, Forecasting Commercial Breakout in 2027
-
Viking Global Technologies Announces Expansion of Grid Protection Technology Pilot with Another Major U.S. Electric Utility
-
Nexscient Reports Third Quarter 2026 Results; Revenue Rises Sequentially as Gross Margin Expands to Over 40%
-
TRNR Reports Record Q3 2026 Results, Driven by 66% Revenue Growth; M&A Pipeline Grows Significantly
-
Ur-Energy Commences Baseline Study Fieldwork; Nears Completion of Technical Report at Lost Soldier Uranium Project, Wyoming
-
How to Turn Your Garage into Usable Living Space
-
Pilot-Founded Solara Global Jet Offers Charter, Leases and Air Cargo Nationwide and Overseas
-
Driving Global Innovation - GTDC Summit APJ Underscores Distribution's Transformative Power
-
InterContinental Hotels Group PLC Announces Transaction in Own Shares - November 17
-
PRAAMS AI Co-Investor Now Covers 400,000+ Global Instruments, With Responses From 3 Seconds, Cost From US$0.01, and Scalability to Millions of Users
-
Broad Clinical Labs Drives Strong Digital Engagement by Connecting Customers with Published Research Through Bioz
-
Razavi Law Group Partners with Chapman University to Prepare the Next Generation of Attorneys
-
ImageWorks Display Advances Whole-Store Solutions with a Re-Imagined Planniq Strong and Planniq Chill
-
KIDZ AI Announces Strategic Collaboration with Synestria to Optimize AI Infrastructure Performance
-
Pivotree Announces Third Quarter 2026 Results
-
MedMira Receives U.S. FDA Breakthrough Device Designation for Its Multiplo(R) Complete Syphilis (TP/nTP) Antibody Test
-
Gabriel Resources Provides Corporate and Financing Update
-
HippoFi Achieves OTCID Market Designation, Opening a New Chapter of Commercial Growth
-
Galway Metals Intersects 1.8 g/t Gold Over 25.0 Metres and 0.7 g/t Gold Over 66.0 Metres at Clarence Stream
-
Avino Announces Key Technical Appointment
-
Brightline Interactive and TruWeather Solutions Sign MOU to Bring Weather Data into SpatialCore Physical AI Platform
-
Can Your Trash Can Pass the Holiday 'Eww' Test?
-
RMTG Expands Cellular Hope Institute's Cancún Clinical Facilities and Longevity Platform
-
Platinum Deck and Patio Announces Nashville, Tennessee Launch
-
Wedgewood Weddings Brings Creekside Mountain Celebrations to Idaho Springs with Blackstone Rivers
-
LIBRA Insurance Partners Welcomes Trawick Financial Services to Its Partner Network
-
FibreSeek Expands U.S. Availability of FibreSeeker 3 with Local Stock and Fulfillment
-
DASI Simulations Named to the 2026 CB Insights' 50 Most Promising Digital Health Startups
-
Islo Secures $15 Million Investment Led by Insight Partners to Scale Enterprise Software Factory Platform
-
Bluedrop Medical Appoints Mark Grant as CEO to Advance Commercialization and Strategic Growth
-
Join Nord Precious Metals' Live Investor Webinar: Advancing Silver Production and High-Grade Exploration in Ontario
-
Who Is the Best Plastic Surgeon in the Pacific Northwest?
-
BHG Financial Closes a New ABS Transaction of $495 Million
-
Spider Labs Upgrades YouTube Placement Exclusions in Spider AF
Evotec SE to announce first half-year results 2025 on 13 August 2025
HAMBURG, DE / ACCESS Newswire / August 6, 2025 / Evotec SE (Frankfurt Stock Exchange:EVT, MDAX/TecDAX, Prime Standard, ISIN: DE0005664809, WKN 566480; NASDAQ:EVO) will announce its half-year interim report for the first six months of 2025 on Wednesday, 13 August 2025.
The Company is going to hold a conference call to discuss the results as well as provide an update on its performance. The conference call will be held in English.
Webcast details
Date: Wednesday, 13 August 2025
Time: 2.00 pm CEST (1.00 pm BST, 8.00 am EDT)
To join the audio webcast and to access the presentation slides, please register via this link.
The on-demand version of the webcast will be available on our website: Financial Publications - Evotec.
Conference call details
To join via phone, please pre-register via this link. You will then receive a confirmation email with dedicated dial-in details such as telephone number, access code and PIN to access the call.
A simultaneous slide presentation for participants dialing in via phone is available under this link .
About Evotec SE
Evotec is a life science company that is pioneering the future of drug discovery and development. By integrating breakthrough science with AI-driven innovation and advanced technologies, we accelerate the journey from concept to cure - faster, smarter, and with greater precision.
Our expertise spans small molecules, biologics, cell therapies and associated modalities, supported by proprietary platforms such as Molecular Patient Databases, PanOmics and iPSC-based disease modeling.
With flexible partnering models tailored to our customers' needs, we work with all Top 20 Pharma companies, over 800 biotechs, academic institutions, and healthcare stakeholders. Our offerings range from standalone services to fully integrated R&D programs and long-term strategic partnerships, combining scientific excellence with operational agility.
Through Just - Evotec Biologics, we redefine biologics development and manufacturing to improve accessibility and affordability.
With a strong portfolio of over 100 proprietary R&D assets, most of them being co-owned, we focus on key therapeutic areas including oncology, cardiovascular and metabolic diseases, neurology, and immunology.
Evotec's global team of more than 4,800 experts operates from sites in Europe and the U.S., offering complementary technologies and services as synergistic centers of excellence. For additional information please go to www.evotec.com and follow us on X/Twitter @Evotec and LinkedIn
Forward-looking statements
This announcement contains forward-looking statements concerning future events, including the proposed offering and listing of Evotec's securities. Words such as "anticipate," "believe," "could," "estimate," "expect," "intend," "may," "might," "plan," "potential," "should," "target," "would" and variations of such words and similar expressions are intended to identify forward-looking statements. Such statements include comments regarding Evotec's expectations for revenues, Group EBITDA and unpartnered R&D expenses. These forward-looking statements are based on the information available to, and the expectations and assumptions deemed reasonable by Evotec at the time these statements were made. No assurance can be given that such expectations will prove to have been correct. These statements involve known and unknown risks and are based upon a number of assumptions and estimates, which are inherently subject to significant uncertainties and contingencies, many of which are beyond the control of Evotec. Evotec expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Evotec's expectations with respect thereto or any change in events, conditions or circumstances on which any statement is based.
For further information, please contact:
Investor Relations
Volker Braun
EVP Head of Global Investor Relations & ESG
[email protected]
SOURCE: Evotec SE
View the original press release on ACCESS Newswire
M.King--AT